AbCellera has been listed alongside a suite of other biotechnology companies, including Moderna, GenScript, and Mammoth Biosciences, that are actively responding to COVIDcampaign-pages/bispecifics/-19. Under the DARPA Pandemic Prevention Platform (P3) program, AbCellera is working to rapidly identify antibodies that can neutralize the virus and potentially block its transmission.
Read full coverage on Forbes.